| Literature DB >> 27326363 |
Abstract
Amyotrophic lateral sclerosis (ALS) misdiagnosis has many broad implications for the patient and the neurologist. Potentially curative treatments exist for certain ALS mimic syndromes, but delay in starting these therapies may have an unfavorable effect on outcome. Hence, it is important to exclude similar conditions. In this review, we discuss some of the important mimics of ALS.Entities:
Keywords: Amyotrophic Lateral Sclerosis; Differential Diagnosis; Motor Neuron Disease
Year: 2016 PMID: 27326363 PMCID: PMC4912674
Source DB: PubMed Journal: Iran J Neurol ISSN: 2008-384X
Diagnostic criteria for amyotrophic lateral sclerosis (ALS)
| The diagnosis of ALS requires the presence of (positive criteria) |
| LMN signs (including EMG features in clinically unaffected muscles) |
| UMN signs |
| Progression of symptoms and signs |
| The diagnosis of ALS requires the absence of (diagnosis by exclusion) |
| Sensory signs |
| Sphincter disturbances |
| Visual disturbances |
| Autonomic features |
| Basal ganglion dysfunction |
| Alzheimer-type dementia |
| ALS “mimic” syndromes |
| The diagnosis of ALS is supported by |
| Fasciculations in one or more regions |
| Neurogenic changes in EMG results |
| Normal motor and sensory nerve conduction |
| Absence of conduction block |
ALS: Amyotrophic lateral sclerosis; EMG: Electromyography; UMN: Upper motor neuron; LMN: Lower motor neuron
El Escorial World Federation of Neurology criteria for diagnosis of amyotrophic lateral sclerosis (ALS)
| Clinically definite ALS |
| UMN and LMN clinical signs or electrophysiological evidence in three regions |
| Clinically definite ALS-laboratory supported |
| UMN and/or LMN clinical signs in one region and the patient is a carrier of a pathogenic SOD1-gene mutation |
| Clinically probable ALS |
| UMN and LMN clinical or electrophysiological evidence by LMN and UMN signs in two regions with some UMN signs rostral to the LMN signs |
| Clinically possible ALS |
| UMN and LMN clinical or electrophysiological signs in one region only, or |
| UMN signs in at least two regions, or |
| UMN and LMN signs in two regions with no UMN signs rostral to LMN signs. Neuroimaging and laboratory studies have excluded other diagnoses. |
ALS: Amyotrophic lateral sclerosis; LMN: Lower motor neuron; UMN: Upper motor neuron, SOD1: Superoxide dismutase 1
Summary of amyotrophic lateral sclerosis (ALS) differential diagnosis
|
|
|
|
|---|---|---|
| CNS ± PNS | Spinocerebellar ataxia type 3 | Prominent extrapyramidal and oculomotor signs |
| Multiple system atrophy | Ataxia, dysautonomia, sphincter disturbance, and oculomotor disturbances | |
| Parkinson’s disease | Tremor and response to levodopa | |
| APBD | Cognitive decline, distal sensory loss, and disturbances of bladder and bowel function | |
| Hex-A deficiency | Cerebellar ataxia, cognitive deterioration, EDX studies may reveal prominent complex repetitive discharges and abnormal SNAPs | |
| Allgrove syndrome | Achalasia, alacrima, adrenocorticotrophic insufficiency, and a broad range of neurological problems | |
| Brainstem and spinal cord | Kennedy’s disease | Mild cognitive impairment; sensory disturbance; and signs of endocrine dysfunction |
| Cervical spondylosis | Prominent neck pain especially with sphincter involvement | |
| Adrenomyeloneuropathy | Increased serum VLCFA, sphincter disturbance, sensory loss | |
| Hereditary spastic paraparesis | family history, very slow progression, sphincter disturbance, absence of LMN, bulbar, or respiratory involvement | |
| Syringomyelia | Dissociated sensory loss, slow progression, younger population | |
| B12 deficiency | Prominent sensory findings | |
| Anterior horn | Post-poliomyelitis syndrome | History of paralytic poliomyelitis, paucity of UMN signs and slow rate of progression |
| Spinal muscular atrophy | Slowly progressive, symmetrical, proximal muscle weakness and atrophy without additional UMN signs | |
| Monomelicamyotrophy | Young men in their second and third decades, relatively sparse fibrillation on needle EMG | |
| Neuropathies and plexopathies | Multifocal motor neuropathy | Absence of muscle atrophy despite very significant weakness, motor weakness is typically restricted to multiple separate peripheral motor nerves, anti GM1 |
| Neuralgic amyotrophy | preceded by significant deep, aching pain, involvement of motor nerve fibers can be curiously patchy | |
| Disorders of the neuromuscular junction | MG | Absence of UMN signs and fasciculations, absence of fibrillation and fasciculation on needle EMG |
| Myopathies | IBM | Absent fasciculations, no UMN signs |
| Oculopharyngeal muscular dystrophy | Involvement of eyelids and extraocular muscles | |
| Isolated neck extensor myopathy | The weakness does not spread to other regions |
EMG: Electromyography; LMN: Lower motor neuron; UMN: Upper motor neuron; IBM: Inclusion body myositis; MG: Myasthenia gravis; VLCFA: Very long chain fatty acids; SNAPs: Sensory nerve action potential; Hex: Hexosaminidase; EDX: Electrodiagnostic; PNS: Peripheral nervous system; CNS: Central nervous system
Diagnosing amyotrophic lateral sclerosis (ALS)/ motor neuron diseases (MND): recommended investigations[37]
|
| |||
|---|---|---|---|
|
|
|
|
|
| Blood | |||
| Erythrocyte sedimentation rate | IV | × | – |
| C-reactive protein | IV | × | – |
| Hematological screen | IV | × | – |
| AST, ALT, LDH | IV | × | – |
| Thyroid function test | IV | × | – |
| Vitamin B12 and folate | IV | × | – |
| Serum protein electrophoresis | IV | × | – |
| Serum immunoelectrophoresis | IV | × | – |
| CK | IV | × | – |
| Creatinine | IV | × | – |
| Electrolytes (Na+, K+, Cl−, Ca2+) | IV | × | – |
| Glucose | IV | × | – |
| Angiotensin-converting enzyme | IV | – | × |
| Lactate | IV | – | × |
| Hex A and B assay | IV | – | × |
| Ganglioside GM-1 antibodies | IV | – | × |
| Anti-Hu, anti-MAG | IV | – | × |
| RA, antinuclear antibodies, anti-DNA | IV | – | × |
| Anti-acetylcholine receptor and anti-muscle-specific receptor tyrosine kinase antibodies | IV | – | × |
| Serology (Borrelia, virus including HIV) | IV | – | × |
| DNA analysis (for SOD1, SMN, SBMA, TDP43, FUS) | IV | – | × |
| CSF | |||
| Cell count | IV | – | × |
| Cytology | IV | – | × |
| Total protein concentration | IV | – | × |
| Glucose, lactate | IV | – | × |
| Protein electrophoresis including IgG index | IV | – | × |
| Serology (Borrelia, virus) | IV | – | × |
| Ganglioside antibodies | IV | – | × |
| Urine | |||
| Cadmium | IV | – | × |
| Lead (24-h secretion) | IV | – | × |
| Mercury | IV | – | × |
| Manganese | IV | – | × |
| Urine immunoelectrophoresis | IV | – | × |
| Neurophysiology | |||
| Electromyography | III | × | – |
| Nerve conduction velocity | III | × | – |
| tcMEP (TMS) | IV | – | × |
| Radiology | – | – | |
| MRI/computed tomography (cranial/cervical, thoracic, lumbar) | IV | × | – |
| Chest X-ray | IV | × | – |
| Mammography | IV | – | × |
| Biopsy | |||
| Muscle | III | – | × |
| Nerve | IV | – | × |
| Bone marrow | IV | – | × |
| Lymph node | IV | – | × |
ASAT: Aspartate aminotransferase, ALAT: Alanine aminotransferase; LDH: Lactate dehydrogenase; CK: Creatine kinase; MAG: Myelin-associated glycoprotein; RA: Rheumatoid arthritis; Hex: Hexosaminidase; HIV: Human immunodeficiency virus; SBMA: Spinobulbar muscular atrophy; SMN: Survival of motor neuron; SOD1: Superoxide dismutase 1; FUS: Fused in sarcoma; TMS: Transcranial magnetic stimulation; MEP: Motor-evoked potentials; IgG: Immunoglobulin G, MRI: Magnetic resonance imaging